PMID- 36480334
OWN - NLM
STAT- MEDLINE
DCOM- 20230309
LR  - 20230320
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 211
IP  - 1
DP  - 2023 Mar 8
TI  - A novel monoclonal antibody with improved FcgammaR blocking ability demonstrated 
      non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at 
      considerably lower dose.
PG  - 23-30
LID - 10.1093/cei/uxac112 [doi]
AB  - Intravenous immunoglobulin (IVIG) is a well-established treatment for various 
      autoimmune and inflammatory diseases. However, the standard dose prescribed for 
      autoimmune diseases, including immune thrombocytopenic purpura (ITP), is 2 g/kg, 
      which is markedly high and leads to a high treatment burden. In this study, we 
      generated fragment crystallizable (Fc)-modified anti-haptoglobin (Hp) monoclonal 
      antibodies with non-inferior efficacy compared to IVIG at considerably lower 
      doses than IVIG, as shown by in vitro experiments. We evaluated binding activity 
      of anti-Hp antibodies to Fc gamma receptors (FcgammaRs) with ELISA and inhibitory 
      activity against the ADCC reaction. Furthermore, we successfully established a 
      novel cynomolgus monkey ITP model and demonstrated that the anti-Hp antibody 
      exerted its effect in this model with only a single dose. This Fc-modified 
      anti-Hp monoclonal antibody could be a valuable therapeutic replacement for IVIG 
      for the treatment of ITP.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the 
      British Society for Immunology.
FAU - Nakajima-Kato, Yuko
AU  - Nakajima-Kato Y
AUID- ORCID: 0000-0002-6373-6256
AD  - Biomedical Science Research Laboratories 2, Research Unit, R&D Division, Kyowa 
      Kirin Co., Ltd., Japan.
AD  - Graduate School of Bio-Applications and Systems Engineering, Tokyo University of 
      Agriculture and Technology, Tokyo, Japan.
FAU - Komai, Masato
AU  - Komai M
AD  - Biomedical Science Research Laboratories 2, Research Unit, R&D Division, Kyowa 
      Kirin Co., Ltd., Japan.
FAU - Yoshida, Tadashi
AU  - Yoshida T
AD  - Graduate School of Bio-Applications and Systems Engineering, Tokyo University of 
      Agriculture and Technology, Tokyo, Japan.
AD  - Department of Applied Biological Science, Tokyo University of Agriculture and 
      Technology, Tokyo, Japan.
FAU - Kanai, Akiko
AU  - Kanai A
AUID- ORCID: 0000-0002-7029-7941
AD  - Biomedical Science Research Laboratories 1, Research Unit, R&D Division, Kyowa 
      Kirin Co., Ltd., Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Receptors, IgG)
SB  - IM
MH  - Animals
MH  - *Purpura, Thrombocytopenic, Idiopathic
MH  - Immunoglobulins, Intravenous
MH  - Macaca fascicularis
MH  - Antibodies, Monoclonal
MH  - Receptors, IgG
PMC - PMC9993454
OTO - NOTNLM
OT  - FcgammaRs
OT  - ITP
OT  - IVIG
OT  - cynomolgus monkey model
OT  - platelets
EDAT- 2022/12/09 06:00
MHDA- 2023/03/10 06:00
PMCR- 2022/12/08
CRDT- 2022/12/08 15:03
PHST- 2022/07/07 00:00 [received]
PHST- 2022/11/04 00:00 [revised]
PHST- 2022/12/06 00:00 [accepted]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2023/03/10 06:00 [medline]
PHST- 2022/12/08 15:03 [entrez]
PHST- 2022/12/08 00:00 [pmc-release]
AID - 6884076 [pii]
AID - uxac112 [pii]
AID - 10.1093/cei/uxac112 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2023 Mar 8;211(1):23-30. doi: 10.1093/cei/uxac112.